Welcome Reception (provided)
Support for this reception is provided by AstraZeneca.

7:00–8:30 p.m.

Group Dinner (provided)

Registration and Continental Breakfast

8:00 a.m.

Welcome and Opening Remarks

8:30 a.m.

Keynote: Applying Behavioral Economics to Health Care Delivery—Innovative Ways to Change Attitudes and Behaviors in the Health Care Setting, Kevin G.M. Volpp, MD, PhD, Wharton, University of Pennsylvania, ACPE #0012-9999-12-224-L04-P (K)
Effective consumer engagement plays a central role in improving health care quality and outcomes by helping facilitate the active involvement of individuals in the management of their health care. However, personal behaviors and the choices people make for themselves have a profound influence on the state of their health. While most people know what they need to do to improve their health, more often than not they fall short when it comes to taking effective action. Behavioral economics not only seeks to understand the powerful forces that impede the achievement of health care goals, but tries to turn those forces to an advantage. This session will focus on innovative ways of applying insights from behavioral economics toward the goal of improving individual health behaviors and positively affecting provider performance.

9:30 a.m.

Break

9:45 a.m.

Panel Discussion: Creating a Culture to Encourage Change, Judith Hibbard, PhD, MPH, University of Oregon; Lance C. Kilpatrick, AARP; Farris K. Timimi, MD, Mayo Clinic, ACPE #0012-9999-12-225-L04-P (A)
Consumer engagement is a key component to the successful promotion of change—and yet, changing and sustaining health-related behaviors is fraught with difficulty. It is well known that in spite of clear-cut warning signs, people tend to continue their unhealthy lifestyles even when they understand the consequences. Our panel members will share their insights on enhancing motivation and improving and sustaining positive health-related behaviors. Topics include the use of social media to improve health care; strategies for effective communication to promote and encourage consumer engagement; the way consumers understand and use health care information; and strategies that have a proven track record of success.

11:15 a.m.

Obesity in Pediatrics: The Impact of a Low-Glycemic Diet to Combat This Epidemic, David S. Ludwig, MD, PhD, Children’s Hospital Boston, ACPE #0012-9999-12-L04-P (K)
According to data from the National Health and Nutrition Examination Survey (NHANES), about one-third of United States adults are obese, and approximately 17 percent of children aged 2–19 years are also classified as obese. The Centers for Disease Control and Prevention (CDC) reports that the incidence of childhood obesity has more than tripled in the past 30 years. This session will focus on the impact of a low-glycemic diet in combating obesity. The groundbreaking research on the use of this diet is the basis for some of the most successful diets of the last decade. The impact of a low-glycemic index diet on combating obesity will be addressed, along with how understanding the impact of all three key factors affecting body weight—biology, behavior, and environment—are a powerful prescription for weight loss.

12:00 p.m.

Lunch (provided)
Support for this lunch is provided by CardioDx.

1:30 p.m.

Keynote: The Twenty-First Century Paradigm Shift—Prevention Rather Than Intervention for the Treatment of Stable Coronary Artery Disease(CAD), Michael D. Ozner, MD, FACC, FAHA, Center for Prevention and Wellness, Baptist Health South Florida; Author, “The Miami Mediterranean Diet”, “The Great American Heart Hoax” and “Heart Attack Proof”, ACPE #0012-9999-12-227-L01-P (K)
CAD is the most common type of heart disease. In the United States, CAD is also the leading cause of death for both men and women. The American Heart Association predicts that by 2030, the direct medical costs of treating heart disease in the U.S. will exceed $1 trillion. Currently—although billions of dollars are spent annually on invasive cardiovascular care, such as angioplasty and coronary artery bypass surgery, and despite the fact that cardiac surgery can be lifesaving—invasive heart procedures benefit only a small fraction of the millions of patients who annually undergo them. This presentation will outline ways in which the management of stable CAD can be improved through aggressive prevention with lifestyle changes and medical therapy instead of through invasive interventions. Those patients with CAD who are likely to have a more-favorable outcome with invasive interventions will also be identified.

2:15 p.m.

Heart Attack Proof—A Six-Week Cardiac Makeover for a Lifetime of Optimal Health, Michael D. Ozner, MD, FACC, FAHA, ACPE #0012-9999-12-228-L01-P (K)
In 2008, over 616,000 or 25 percent of the deaths recorded in the United States were due to heart disease (Source: CDC). According to a recent study by the American Heart Association, by 2030 two-out-of-five Americans will have some form of cardiovascular disease. This session will focus on a six-week cardiac makeover that can help patients prevent and reverse heart disease, even individuals who have had previous cardiac surgery.

3:00 p.m.

Break

3:15 p.m.

The Role of Pharmacogenomics in the Future of Health Care, Peter H. O'Donnell, MD, The University of Chicago Medicine, ACPE #0012-9999-12-229-L01-P (K)
Pharmacogenomics is the study of genetic variations that influence individual response to drugs. The identification of genetic factors that influence drug absorption, metabolism, and action at the receptor level should, in theory, allow for individualized therapy, holding the promise that drug therapy might one day be personalized to reflect each person’s unique genetic makeup.
Despite the promise of pharmacogenetics in potentially increasing drug efficacy and safety, the era of widespread application of pharmacogenomics has not yet arrived. This presentation will provide an overview of the current status of pharmacogenomics, the challenges this field faces and its likely evolution over the next several years.

4:00–5:00 p.m.

Ethical Issues Surrounding Pharmacogenetics/Genomics, Jeffrey Kahn, PhD, MPH, Johns Hopkins Berman Institute of Bioethics, ACPE #0012-9999-12-230-L04-P (K)
This session will review ethical issues associated with developments in the field of pharmacogenetics. These concerns include implications for the cost of drug development and availability of potentially very expensive medicines—especially for those individuals with rare pharmacogenetic variations that are likely to lead to abnormalities in both those drugs’ efficacy and side effects profile. The session will also tackle challenges related to the use and storage of genetic information obtained from pharmacogenetic analyses.

5:00–7:00 p.m.

Reception and Exhibits (provided)
Join your colleagues for complimentary hors d’oeuvres and beverages. You won’t want to miss this opportunity to gather information and ideas from exhibitors from a variety of industry organizations.